SCHEMBL13822233

SCHEMBL13822233

CC(C)CC(N)C[C@H](O)NC=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 8/20 0.37
ERAP1 Q9NZ08 2/20 0.37
ERAP2 Q6P179 1/20 0.37
DNPEP Q9ULA0 2/20 0.36
ADH1B P00325 2/20 0.36
ADH1C P00326 2/20 0.36
ADH1A P07327 2/20 0.36
TSHR P16473 2/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
NFKB1 P19838 1/20 0.35
THPO P40225 1/20 0.35
GMNN O75496 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
PMP22 Q01453 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
SLC7A5 Q01650 1/20 0.34
LAP3 P28838 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14115916 0.74 ANPEP (0.35) ANPEPERAP1ERAP2ADH1BADH1C
SCHEMBL14927643 0.72
SCHEMBL11122409 0.72
SCHEMBL18563053 0.72
SCHEMBL11961906 0.71 GABBR2 (0.40) ANPEPDNPEPADH1BADH1CADH1A
SCHEMBL6756348 0.71 GABBR2 (0.40) ANPEPDNPEPADH1BADH1CADH1A
SCHEMBL11012918 0.69 ANPEP (0.38) ANPEPERAP1ERAP2DNPEPTSHR
SCHEMBL56311 0.69 ANPEP (0.65) ANPEPERAP1ERAP2TSHRCYP3A4
SCHEMBL802822 0.68 ANPEP (0.50) ANPEPERAP1ERAP2DNPEPTSHR
SCHEMBL10343746 0.67 ANPEP (0.61) ANPEPERAP1ERAP2TSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156472-A1 Cyclic Depsipeptides NOVARTIS AG (CH) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156472-A1 Cyclic Depsipeptides SERPINB1, ELANE, KLK7 ANPEP 25/4885ERAP1 124/4885ERAP2 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.